```
09839289 Page 1
```

Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID:ssspta1611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
 NEWS
                  Web Page URLs for STN Seminar Schedule - N. America
                  "Ask CAS" for self-help around the clock
 NEWS
       2 Apr 08
 NEWS
                  BEILSTEIN: Reload and Implementation of a New Subject Area
       3 Apr 09
 NEWS
                  ZDB will be removed from STN
 NEWS
       5 Apr 19
                 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
 NEWS 6 Apr 22
                 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
 NEWS 7 Apr 22
                  BIOSIS Gene Names now available in TOXCENTER
 NEWS 8 Apr 22
                  Federal Research in Progress (FEDRIP) now available
 NEWS 9
                 New e-mail delivery for search results now available
         Jun 03
 NEWS 10 Jun 10
                 MEDLINE Reload
 NEWS 11
                  PCTFULL has been reloaded
         Jun 10
 NEWS 12 Jul 02
                 FOREGE no longer contains STANDARDS file segment
 NEWS 13 Jul 22
                 USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14
                 Enhanced polymer searching in REGISTRY
         Jul 29
NEWS 15
         Jul 30
                 NETFIRST to be removed from STN
NEWS 16 Aug 08
                 CANCERLIT reload
NEWS 17
                 PHARMAMarketLetter(PHARMAML) - new on STN
         Aug 08
NEWS 18
         Aug 08
                 NTIS has been reloaded and enhanced
NEWS 19
                 Aquatic Toxicity Information Retrieval (AQUIRE)
         Aug 19
                 now available on STN
NEWS 20
         Aug 19
                 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21
                 The MEDLINE file segment of TOXCENTER has been reloaded
         Aug 19
NEWS 22
                 Sequence searching in REGISTRY enhanced
         Aug 26
NEWS 23
         Sep 03
                 JAPIO has been reloaded and enhanced
NEWS 24
                 Experimental properties added to the REGISTRY file
         Sep 16
                 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 25
         Sep 16
NEWS 26
                 CA Section Thesaurus available in CAPLUS and CA
         Sep 16
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS
             October 14 CURRENT WINDOWS VERSION IS V6.01,
              CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
             AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
             Welcome Banner and News Items
NEWS PHONE
             Direct Dial and Telecommunication Network Access to STN
```

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:49:30 ON 17 OCT 2002

=> file registry

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

TOTAL

ENTRY

SESSION

0.21 0.21

FILE 'REGISTRY' ENTERED AT 16:49:42 ON 17 OCT 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1 DICTIONARY FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> Uploading 29839289.str

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1

STR

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 16:50:08 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -3 TO ITERATE

100.0% PROCESSED SEARCH TIME: 00.00.01

3 ITERATIONS

1 ANSWERS

FULL FILE PROJECTIONS:

ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

3 TO 163

PROJECTED ANSWERS:

1 TO 80

L2

1 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:50:16 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -12 TO ITERATE

100.0% PROCESSED

12 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.02

L3

1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY SESSION 140.28

140.49

FILE 'CAPLUS' ENTERED AT 16:50:24 ON 17 OCT 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

Patel

<10/17/2002>

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2002 VOL 137 ISS 16 FILE LAST UPDATED: 16 Oct 2002 (20021016/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 11

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 16:50:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED

3 ITERATIONS

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS:

SEARCH TIME: 00.00.01

3 TO 163

PROJECTED ANSWERS:

1 TO 80

L4

1 SEA SSS SAM L1

L5 5 L4

=> d f bib hitstr abs total
'F' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default) CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

```
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
             SCAN must be entered on the same line as the DISPLAY,
             e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL
IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ---- STD, indented with text labels
OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels
SBIB ---- BIB, no citations
SIBIB ---- IBIB, no citations
HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
             containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
             structure diagram, plus NTE and SEQ fields
FHITSTR ---- First HIT RN, its text modification, its CA index name, and
             its structure diagram
FHITSEQ ---- First HIT RN, its text modification, its CA index name, its
             structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number. ENTER DISPLAY FORMAT (BIB):bib

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS

```
09839289 Page 6
```

```
AN
      2002:51464 CAPLUS
 DN
      136:112673
 TI
     Methods using a purine derivative, pyrimidine derivative, or
     tetrahydroindolone derivative for treatment of disease-induced peripheral
     neuropathy and related conditions
 IN
     Diamond, Jack; Glasky, Alvin J.
 PA
     Neotherapeutics, Inc., USA
     PCT Int. Appl., 69 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 2
     PATENT NO.
                      KIND DATE
                                           APPLICATION NO. DATE
                                            -----
                                                            -----
PI
     WO 2002004452
                      A2
                            20020117
                                           WO 2001-US21526 20010706
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, FD, TG
     AU 2001071908
                       Α5
                            20020121
                                           AU 2001-71908
                                                         /20010706
     US 2002055506
                       Α1
                            20020509
                                           US 2001-900844
                                                            20010706
     US 2002061899
                       A1
                                           US 2001-899901
                            20020523
                                                            20010706
PRAI US 2000-216844P
                       Ρ
                            20000707
     WO 2001-US21526
                       W
                            20010706
os
     MARPAT 136:112673
L_5
     ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
     2002:51463 CAPLUS
AN
DN
     136:112672
     Methods using a purine derivative, pyrimidine derivative, or
TΙ
     tetrahydroindolone derivative for stimulation of synthesis of
     synaptophysin in the central nervous system
     Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
IN
PA
     Neotherapeutics, Inc., USA
SO
     PCT Int. Appl., 59 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
    PATENT NO.
                      KIND DATE
                                          APPLICATION NO.
                     ----
                                          -----
ΡI
    WO 2002004451
                      A2
                            20020117
                                         WO 2001-US21385 20010706
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
```

```
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2002040032
                      A1
                            20020404
                                        US 2001-899478 20010705
     AU 2001073218
                       A5
                            20020121
                                          AU 2001-73218
                                                          20010706
PRAI US 2000-216808P
                       Ρ
                            20000707
     WO 2001-US21385
                       W
                            20010706
OS
     MARPAT 136:112672
L5
     ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN
     2002:51462 CAPLUS
DN
     136:112671
TΙ
     Methods using a purine derivative, pyrimidine derivative, or
     tetrahydroindolone derivative for prevention of accumulation of amyloid
     .beta. peptide in the central nervous system
     Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
IN
PA
     Neotherapeutics, Inc., USA
SO
     PCT Int. Appl., 56 pp.
     CODEN: PIXXD2
DT Patent
LΑ
    English
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                        APPLICATION NO. DATE
     WO 2002004450 A2 20020117 WO 2001-US21384 20010706
PΙ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2002040031
                                       US 2001-899611 20010705
                     A1 20020404
    AU 2001073217
                      Α5
                           20020121
                                         AU 2001-73217
                                                          20010706
PRAI US 2000-216845P
                      Р
                           20000707
    WO 2001-US21384
                     W
                           20010706
OS
    MARPAT 136:112671
    ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS
L5
ΑN
    2002:51461 CAPLUS
DN
     136:112691
    Methods using a purine derivative, a pyrimidine derivative or a
ΤI
    tetrahydroindolone derivative for treatment of conditions affected by
    activity of multidrug transporters
IN
    Taylor, Eve M.
PΑ
    Neotherapeutics, Inc., USA
SO
    PCT Int. Appl., 70 pp.
    CODEN: PIXXD2
DT
    Patent
LΑ
    English
FAN.CNT 1
    PATENT NO. KIND DATE
                                        APPLICATION NO. DATE
                    ----
```

```
PΙ
      WO 2002004449
                        A2
                              20020117
                                             WO 2001-US21383 20010706
      WO 2002004449
                        А3
                              20020613
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
              HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
              LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
              SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
              YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      US 2002128264
                        A1
                             20020912
                                           US 2001-90029<u>7</u> 20010706
PRAI US 2000-216616P
                        Ρ
                              20000707
OS
     MARPAT 136:112691
     ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS
L5
AN
      2002:51460 CAPLUS
DN
      136:112670
     Methods using purine derivatives, pyrimidine derivatives, and
TI
     tetrahydroindolone derivatives for treatment of drug-induced peripheral
     neuropathy and related conditions
IN
     Diamond, Jack; Glasky, Alvin J.
PA
     Neotherapeutics, Inc., USA
SO
     PCT Int. Appl., 66 pp.
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 2
     PATENT NO.
                      KIND DATE
                                            APPLICATION NO.
                                                              DATE
                       ____
                             -----
                                             -----
PΙ
     WO 2002004448
                      A2
                             20020117
                                            WO 2001-US21373 20010706
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2001073212
                             20020121
                       Α5
                                           AU 2001-73212
                                                              20010706
     US 2002055506
                       Α1
                             20020509
                                            US 2001-900844
                                                              20010706
     US 2002061899
                       Α1
                             20020523
                                            US 2001-899901
PRAI US 2000-216844P
                        Ρ
                             20000707
     WO 2001-US21373
                       W
                             20010706
     MARPAT 136:112670
=> log y
COST IN U.S. DOLLARS
                                                  SINCE FILE
                                                                   TOTAL
                                                        ENTRY
                                                                 SESSION
FULL ESTIMATED COST
                                                         5.57
                                                                  146.84
```

CODEN: PIXXD2

```
DT
     Patent
LA
     English
FAN.CNT 2
     PATENT NO.
                      KIND
                            DATE
                                           APPLICATION NO.
                                                            DATE
                      ____
                                           -----
PΙ
     WO 2002004452
                      A2
                            20020117
                                           WO 2001-US21526 20010706
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                           US 2000-216844PP 20000707
     AU 2001071908
                       A5
                            20020121
                                           AU 2001-71908
                                                             20010706
                                           US 2000-216844PP 20000707
                                           WO 2001-US21526W 20010706
     US 2002055506
                       Α1
                            20020509
                                           US 2001-900844
                                                            20010706
                                           US 2000-216844PP 20000707
     US 2002061899
                       A1
                            20020523
                                           US 2001-899901
                                                            20010706
                                           US 2000-216844PP 20000707
PATENT FAMILY INFORMATION:
FAN
     2002:51460
     PATENT NO.
                      KIND
                            DATE
                                           APPLICATION NO. DATE
                      ____
                            -----
                                           -----
                                                            _____
ΡI
     WO 2002004448
                     A2
                            20020117
                                           WO 2001-US21373 20010706
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                           US 2000-216844PP 20000707
    AU 2001073212
                       Α5
                            20020121
                                           AU 2001-73212
                                                            20010706
                                           US 2000-216844PP 20000707
                                           WO 2001-US21373W 20010706
    US 2002055506
                       A1
                            20020509
                                           US 2001-900844
                                                            20010706
                                           US 2000-216844PP 20000707
    US 2002061899
                       A1
                            20020523
                                           US 2001-899901
                                                            20010706
                                           US 2000-216844PP 20000707
OS
    MARPAT 136:112673
IT
    389799-42-2
    RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (purine derivs., pyrimidine derivs., and tetrahydroindolone derivs.
for
       treatment of disease-induced peripheral neuropathy and related
       conditions)
```

RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

AB A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.

```
L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
```

AN 2002:51463 CAPLUS

DN 136:112672

TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

```
PATENT NO.
                      KIND
                            DATE
                                           APPLICATION NO.
                                                             DATE
                      ____
PΙ
     WO 2002004451
                      A2
                            20020117
                                           WO 2001-US21385
                                                            20010706
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                           US 2000-216808PP 20000707
    US 2002040032
                      A1
                            20020404
                                           US 2001-899478
                                                            20010705
                                           US 2000-216808PP 20000707
    AU 2001073218
                      Α5
                            20020121
                                           AU 2001-73218
                                                            20010706
```

US 2000-216808PP 20000707 WO 2001-US21385W 20010706

OS MARPAT 136:112672


IT 389799-42-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for stimulation of synthesis of synaptophysin in CNS)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of increasing the synthesis and/or secretion of synaptphysin comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. of analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety

be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred

purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

- L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
- AN 2002:51462 CAPLUS
- DN 136:112671
- TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid .beta. peptide in the central nervous system
- IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
- PA Neotherapeutics, Inc., USA
- SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE ----------------PΙ WO 2002004450 A2 20020117 WO 2001-US21384 20010706 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 2000-216845PP 20000707 US 2002040031 20020404 Α1 US 2001-899611 20010705 US 2000-216845PP 20000707 AU 2001073217 **A5** 20020121 AU 2001-73217 20010706 US 2000-216845PP 20000707 WO 2001-US21384W 20010706

OS MARPAT 136:112671

IT 389799-42-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for prevention of accumulation of amyloid .beta. peptide in CNS)

RN 389799-42-2 CAPLUS

Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

AB A method of either inhibiting the formation of A.beta. or stimulating the formation of sAPP comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred

purine deriv. is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

- L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS
- AN 2002:51461 CAPLUS
- DN 136:112691
- TI Methods using a purine derivative, a pyrimidine derivative or a tetrahydroindolone derivative for treatment of conditions affected by activity of multidrug transporters
- IN Taylor, Eve M.
- PA Neotherapeutics, Inc., USA
- SO PCT Int. Appl., 70 pp. CODEN: PIXXD2
- DT Patent
- LA English

```
FAN.CNT 1
```

	PATENT NO.				KIND		DATE			APPLICATION NO.					DATE			
PI		2002004449 2002004449					20020117 20020613			WO 2001-US21383					20010706			
			CR, HU, LU, SD, YU,	CU, ID, LV, SE, ZA,	CZ, IL, MA, SG, ZW,	DE, IN, MD, SI, AM,	DK, IS, MG, SK, AZ,	DM, JP, MK, SL, BY,	DZ, KE, MN, TJ, KG,	EE, KG, MW, TM, KZ,	ES, KP, MX, TR, MD,	FI, KR, MZ, TT, RU,	GB, KZ, NO, TZ, TJ,	GD, LC, NZ, UA, TM	BZ, GE, LK, PL, UG,	GH, LR, PT, US,	GM, LS, RO, UZ,	HR, LT, RU, VN,
	US 2		DE, BJ,	DK, CF,	ES,	FI, CI,	FR,	GB, GA,	GR,	IE, GW, U:	IT, ML, 5 200	LU, MR, 00-2:	MC, NE, 1661 0029	NL, SN, 6PP 7	PT, TD, 20000	SE, TG 0707 0706	TR,	BF,

OS MARPAT 136:112691

IT 389799-42-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

 ${\tt AB}$ One aspect of the invention is a method of treating a condition or disease

assocd. with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease assocd. with the activity of a multidrug transporter protein an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine

moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer,

a microbial or parasitic infection, HIV, infection, or a condition assocd.

with inflammation, e.g. asthma or rheumatic disease.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS

```
2002:51460 CAPLUS
AN
DN
     136:112670
ΤI
     Methods using purine derivatives, pyrimidine derivatives, and
     tetrahydroindolone derivatives for treatment of drug-induced peripheral
     neuropathy and related conditions
IN
     Diamond, Jack; Glasky, Alvin J.
PA
     Neotherapeutics, Inc., USA
SO
     PCT Int. Appl., 66 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 2
     PATENT NO.
                        KIND DATE
                                               APPLICATION NO.
                                                                DATE
                       ____
PΙ
     WO 2002004448
                        A2
                              20020117
                                              WO 2001-US21373 20010706
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
              HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
              LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
              SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
              YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                               US 2000-216844PP 20000707
     AU 2001073212
                         A5
                              20020121
                                               AU 2001-73212
                                                                 20010706
                                               US 2000-216844PP 20000707
                                               WO 2001-US21373W 20010706
     US 2002055506
                         A1
                              20020509
                                               US 2001-900844
                                                                 20010706
                                               US 2000-216844PP 20000707
     US 2002061899
                         A1
                              20020523
                                               US 2001-899901
                                                                 20010706
                                               US 2000-216844PP 20000707
PATENT FAMILY INFORMATION:
FAN
    2002:51464
     PATENT NO.
                       KIND
                              DATE
                                              APPLICATION NO. DATE
     -----
                                              ______
ΡI
     WO 2002004452
                       A2
                              20020117
                                              WO 2001-US21526 20010706
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
         SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                              US 2000-216844PP 20000707
    AU 2001071908
                        A5
                              20020121
                                              AU 2001-71908
                                                                 20010706
                                              US 2000-216844PP 20000707
                                              WO 2001-US21526W 20010706
    US 2002055506
                        A1
                              20020509
                                              US 2001-900844
                                                                 20010706
                                              US 2000-216844PP 20000707
    US 2002061899
                        A1
                              20020523
                                              US 2001-899901
                                                                 20010706
                                              US 2000-216844PP 20000707
```

OS MARPAT 136:112670

IT 389799-42-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs.

for

treatment of drug-induced peripheral neuropathy and related conditions)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy assocd. with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin,

altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly

useful in treating peripheral neuropathy assocd. with the administration of vincristine, paclitaxel, or cisplatin.

=> log y COST IN U.S. DOLLARS SINCE FILE TOTAL. ENTRY SESSION FULL ESTIMATED COST 33.85 175.50 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -3.10-3.10

STN INTERNATIONAL LOGOFF AT 16:42:17 ON 17 OCT 2002